![]() |
Name |
Pyrenosetin C
|
Molecular Formula | C25H33NO5 | |
IUPAC Name* |
(2R,3R,3aS,5'R,5aR,7S,9aS,9bR)-5'-(hydroxymethyl)-1',4,7,9b-tetramethyl-3-(3-oxobut-1-enyl)spiro[3,3a,5a,6,7,8,9,9a-octahydrocyclopenta[a]naphthalene-2,3'-pyrrolidine]-1,2',4'-trione
|
|
SMILES |
C[C@H]1CC[C@H]2[C@H](C1)C=C([C@H]3[C@@]2(C(=O)[C@]4([C@@H]3C=CC(=O)C)C(=O)[C@H](N(C4=O)C)CO)C)C
|
|
InChI |
InChI=1S/C25H33NO5/c1-13-6-8-17-16(10-13)11-14(2)20-18(9-7-15(3)28)25(22(30)24(17,20)4)21(29)19(12-27)26(5)23(25)31/h7,9,11,13,16-20,27H,6,8,10,12H2,1-5H3/t13-,16+,17-,18+,19+,20+,24+,25-/m0/s1
|
|
InChIKey |
LQXNTMMEAPEMLM-DMLHXFJKSA-N
|
|
Synonyms |
Pyrenosetin C
|
|
CAS | NA | |
PubChem CID | 156581893 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 427.5 | ALogp: | 2.7 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 91.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.424 |
Caco-2 Permeability: | -4.894 | MDCK Permeability: | 0.00002070 |
Pgp-inhibitor: | 0.993 | Pgp-substrate: | 0.87 |
Human Intestinal Absorption (HIA): | 0.294 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.04 |
Blood-Brain-Barrier Penetration (BBB): | 0.931 | Plasma Protein Binding (PPB): | 69.31% |
Volume Distribution (VD): | 0.881 | Fu: | 28.05% |
CYP1A2-inhibitor: | 0.007 | CYP1A2-substrate: | 0.331 |
CYP2C19-inhibitor: | 0.061 | CYP2C19-substrate: | 0.865 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.068 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.058 |
CYP3A4-inhibitor: | 0.389 | CYP3A4-substrate: | 0.918 |
Clearance (CL): | 9.765 | Half-life (T1/2): | 0.4 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.07 |
Drug-inuced Liver Injury (DILI): | 0.477 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.356 | Maximum Recommended Daily Dose: | 0.876 |
Skin Sensitization: | 0.73 | Carcinogencity: | 0.927 |
Eye Corrosion: | 0.024 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.972 |